ZFIN ID: ZDB-FIG-151125-22
Okuda et al., 2015 - A zebrafish model of inflammatory lymphangiogenesis. Biology Open   4(10):1270-80 Full text @ Biol. Open
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Conditions:
Anatomical Terms:
Stage: Days 7-13
PHENOTYPE:
Fish:
Conditions:
Observed In:
Stage: Days 7-13

Fig. 5

Macrophages are required for intestinal inflammatory lymphangiogenesis. (A) Schema outlining metronidazole and TNBS treatments. (B) Lateral image of the intestine in 7dpf lyve1:DsRed2; kdrl:EGFP larvae exposed to TNBS+2.5mM metronidazole (Met). (C,D), Lateral image of the intestine in 7dpf lyve1:DsRed2;kdrl:EGFP;mpeg1:Gal4FF;UAS:nfsB:mCherry larvae exposed to TNBS (C) and TNBS+2.5mM metronidazole (D). (E,F), Lateral image of the intestine in 7dpf lyve1:DsRed2;kdrl:EGFP;mpx:KalTA4;UAS:nfsB:mCherry larvae exposed to TNBS (E) and TNBS+2.5mM metronidazole (F). (B2-F2) shows expression in the DsRed/mCherry channel only. Asterisks indicate intestinal lymphatic sprouts (ILSs). (G,H) FACS analysis of mCherry-positive cell counts from TNBS-treated (control) and TNBS+2.5mM metronidazole-treated 3 and 7dpf mpeg1:Gal4FF;UAS:nfsB:mCherry larvae (G) or mpx:KalTA4;UAS:nfsB:mCherry larvae (H) (ne3, each replicate contains 30–80 larvae). (I,J) Quantification of ILS number (I) and total ILS length (J) (ne17). Error bars, ±s.d. n.s. P>0.05, *P<0.05, **P<0.01, ***P<0.001, by unpaired t-test (G,H) or by one-way ANOVA with Tukey′s multiple comparison test (I,J). TD, thoracic duct. Scale bar: 100µm.
Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
DsRed c264Tg; gl25Tg; nz101Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network IFL
Days 7-13 intestinal lymphatic network lymphangiogenic sprout IFL
Days 7-13 lymphatic system IFL
Days 7-13 thoracic duct IFL
c264Tg; gl25Tg; nz101Tg; s843Tg chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network IFL
Days 7-13 intestinal lymphatic network lymphangiogenic sprout IFL
Days 7-13 lymphatic system IFL
Days 7-13 thoracic duct IFL
c264Tg; gl28Tg; nz150Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network IFL
Days 7-13 intestinal lymphatic network lymphangiogenic sprout IFL
Days 7-13 lymphatic system IFL
Days 7-13 thoracic duct IFL
c264Tg; gl28Tg; nz150Tg; s843Tg chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network IFL
Days 7-13 intestinal lymphatic network lymphangiogenic sprout IFL
Days 7-13 lymphatic system IFL
Days 7-13 thoracic duct IFL
nz101Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network IFL
Days 7-13 intestinal lymphatic network lymphangiogenic sprout IFL
Days 7-13 lymphatic system IFL
Days 7-13 thoracic duct IFL
EGFP c264Tg; gl25Tg; nz101Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 blood vasculature IFL
Days 7-13 intestine blood vasculature IFL
c264Tg; gl25Tg; nz101Tg; s843Tg chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 blood vasculature IFL
Days 7-13 intestine blood vasculature IFL
c264Tg; gl28Tg; nz150Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 blood vasculature IFL
Days 7-13 intestine blood vasculature IFL
c264Tg; gl28Tg; nz150Tg; s843Tg chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 blood vasculature IFL
Days 7-13 intestine blood vasculature IFL
nz101Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 blood vasculature IFL
Days 7-13 intestine blood vasculature IFL
mCherry c264Tg; gl25Tg; nz101Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 macrophage IFL
c264Tg; gl25Tg; nz101Tg; s843Tg chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 macrophage IFL
c264Tg; gl28Tg; nz150Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 neutrophil IFL
c264Tg; gl28Tg; nz150Tg; s843Tg chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 neutrophil IFL
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
c264Tg; gl25Tg; nz101Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network lymphangiogenesis process quality, ameliorated
Days 7-13 intestinal lymphatic network lymphangiogenic sprout amount, ameliorated
Days 7-13 macrophage decreased amount, abnormal
c264Tg; gl25Tg; nz101Tg; s843Tg chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network lymphangiogenesis increased process quality, abnormal
Days 7-13 intestinal lymphatic network lymphangiogenic sprout increased amount, abnormal
c264Tg; gl28Tg; nz150Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network lymphangiogenesis increased process quality, abnormal
Days 7-13 intestinal lymphatic network lymphangiogenic sprout increased amount, abnormal
Days 7-13 neutrophil decreased amount, abnormal
c264Tg; gl28Tg; nz150Tg; s843Tg chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network lymphangiogenesis increased process quality, abnormal
Days 7-13 intestinal lymphatic network lymphangiogenic sprout increased amount, abnormal
nz101Tg; s843Tg chemical treatment: metronidazole, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Days 7-13 intestinal lymphatic network lymphangiogenesis increased process quality, abnormal
Days 7-13 intestinal lymphatic network lymphangiogenic sprout increased amount, abnormal
Acknowledgments:
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Biol. Open
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.